Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry.
TAVI
TAVR
anemia
female
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
24
08
2020
accepted:
05
09
2020
pubmed:
2
10
2020
medline:
21
9
2021
entrez:
1
10
2020
Statut:
ppublish
Résumé
To assess the impact of anemia on clinical outcomes in female patients enrolled in the Women's InterNational transcatheter aortic valve implantation (WIN-TAVI) registry. Anemia is highly prevalent among females who constitute half of TAVI candidates, yet, its clinical significance remains poorly investigated. Patients were divided into three groups according to preprocedural hemoglobin (Hb) level: (1) no anemia (Hb ≥12 g/dl), (2) mild-to-moderate anemia (10 ≤ Hb <12 g/dl), and (3) severe anemia (Hb <10 g/dl). The primary outcome was the occurrence of Valve Academic Research Consortium (VARC)-2 efficacy endpoint, a composite of mortality, stroke, myocardial infarction (MI), hospitalization for valve-related symptoms or heart failure or valve-related dysfunction at 1-year follow-up. Hemoglobin level was available in 877 (86.1%) patients: 412 (47.0%) had no anemia, 363 (41.4%) had mild-to-moderate anemia, and 102 (11.6%) had severe anemia. The latter group had a higher prevalence of cardiovascular risk factors. Compared with patients without anemia, severe anemia was associated with a greater risk of VARC-2 efficacy endpoint ( Severe anemia in females undergoing TAVI was independently associated with increased rates of VARC-2 efficacy endpoint and mortality at 1 year.
Sections du résumé
OBJECTIVES
To assess the impact of anemia on clinical outcomes in female patients enrolled in the Women's InterNational transcatheter aortic valve implantation (WIN-TAVI) registry.
BACKGROUND
Anemia is highly prevalent among females who constitute half of TAVI candidates, yet, its clinical significance remains poorly investigated.
METHODS
Patients were divided into three groups according to preprocedural hemoglobin (Hb) level: (1) no anemia (Hb ≥12 g/dl), (2) mild-to-moderate anemia (10 ≤ Hb <12 g/dl), and (3) severe anemia (Hb <10 g/dl). The primary outcome was the occurrence of Valve Academic Research Consortium (VARC)-2 efficacy endpoint, a composite of mortality, stroke, myocardial infarction (MI), hospitalization for valve-related symptoms or heart failure or valve-related dysfunction at 1-year follow-up.
RESULTS
Hemoglobin level was available in 877 (86.1%) patients: 412 (47.0%) had no anemia, 363 (41.4%) had mild-to-moderate anemia, and 102 (11.6%) had severe anemia. The latter group had a higher prevalence of cardiovascular risk factors. Compared with patients without anemia, severe anemia was associated with a greater risk of VARC-2 efficacy endpoint (
CONCLUSION
Severe anemia in females undergoing TAVI was independently associated with increased rates of VARC-2 efficacy endpoint and mortality at 1 year.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E704-E715Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Makkar RR, Thourani VH, Mack MJ, et al. Five-year outcomes of Transcatheter or surgical aortic-valve replacement. N Engl J Med. 2020;382(9):799-809.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.
Krasopoulos G, Falconieri F, Benedetto U, et al. European real world trans-catheter aortic valve implantation: systematic review and meta-analysis of European national registries. J Cardiothorac Surg. 2016;11(1):159.
Chieffo A, Petronio AS, Mehilli J, Chandrasekhar J, Sartori S, Lefèvre T, Presbitero P, Capranzano P, Tchetche D, Iadanza A, Sardella G, van Mieghem N, Meliga E, Dumonteil N, Fraccaro C, Trabattoni D, Mikhail G, Sharma S, Ferrer MC, Naber C, Kievit P, Baber U, Snyder C, Sharma M, Morice MC, Mehran R, WIN-TAVI Investigators. 1-year clinical outcomes in women after transcatheter aortic valve replacement: results from the first WIN-TAVI registry. JACC Cardiovasc Interv 2018;11(1):1-12.
Arnold SV, Spertus JA, Vemulapalli S, et al. Quality-of-life outcomes after transcatheter aortic valve replacement in an unselected population: a report from the STS/ACC Transcatheter valve therapy registry. JAMA Cardiol. 2017;2(4):409-416.
Piankova P, Afilalo J. Prevalence and prognostic implications of frailty in Transcatheter aortic valve replacement. Cardiol Clin. 2020;38(1):75-87.
Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RCJB. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263-2268.
Rheude T, Pellegrini C, Michel J, et al. Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. Int J Cardiol. 2017;244:93-99.
Kodali S, Williams MR, Doshi D, et al. Sex-specific differences at presentation and outcomes among patients undergoing transcatheter aortic valve replacement: a cohort study. Ann Intern Med. 2016;164(6):377-384.
Chandrasekhar J, Dangas G, Yu J, et al. Sex-based differences in outcomes with transcatheter aortic valve therapy: TVT registry from 2011 to 2014. J Am Coll Cardiol. 2016;68(25):2733-2744.
O'Connor SA, Morice M-C, Gilard M, et al. Revisiting sex equality with transcatheter aortic valve replacement outcomes: a collaborative, patient-level meta-analysis of 11,310 patients. J Am Coll Cardiol. 2015;66(3):221-228.
Vlastra W, Chandrasekhar J, García Del Blanco B, et al. Sex differences in Transfemoral Transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;74(22):2758-2767.
Nagao K, Taniguchi T, Morimoto T, et al. Anemia in patients with severe aortic stenosis. Sci Rep. 2019;9(1):1924-1924.
Chieffo A, Petronio AS, Mehilli J, et al. Acute and 30-day outcomes in women after TAVR: results from the WIN-TAVI (Women's INternational Transcatheter aortic valve implantation) real-world registry. JACC Cardiovasc Interv. 2016;9(15):1589-1600.
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Journal International de Bioethique (Int J Bioethic). 2004;15(1):124-129.
WHO. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5-37.
Nuis R-J, Rodés-Cabau J, Sinning J-M, et al. Blood transfusion and the risk of acute kidney injury after transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2012;5(5):680-688.
Arai T, Morice M-C, O'Connor SA, et al. Impact of pre- and post-procedural anemia on the incidence of acute kidney injury and 1-year mortality in patients undergoing transcatheter aortic valve implantation (from the French aortic national CoreValve and Edwards 2 [France 2] registry). Catheter Cardiovasc Interv. 2015;85(7):1231-1239.
De Backer O, Arnous S, Lønborg J, et al. Recovery from anemia in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation- -prevalence, predictors and clinical outcome. PLoS ONE. 2014;9(12):e114038.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document. J Am Coll Cardiol. 2012;60(15):1438-1454.
Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J. 2018;39(28):2635-2642.
Nuis R-J, Sinning J-M, Rodés-Cabau J, et al. Prevalence, factors associated with, and prognostic effects of preoperative anemia on short-and long-term mortality in patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2013;6(6):625-634.
Van Mieghem NM, Nuis R-J, Tzikas A, et al. Prevalence and prognostic implications of baseline anaemia in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2011;7(2):184-191.
Escárcega RO, Lipinski MJ, Magalhaes MA, et al. Impact of blood transfusions on short- and long-term mortality in patients who underwent transcatheter aortic valve implantation. Am J Cardiol. 2015;115(1):93-99.
Lv Z, Zhou B, Yang C, Wang H. Preoperative Anemia and postoperative mortality in patients with aortic stenosis treated with Transcatheter aortic valve implantation (TAVI): a systematic review and meta-analysis. Med Sci Monit. 2019;25:7251-7257.
Seiffert M, Conradi L, Gutwein A, et al. Baseline anemia and its impact on midterm outcome after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2017;89(1):E44-E52.
van Straten AH, Külcü K, Özdemir HI, Elenbaas TW, Soliman Hamad MA. Preoperative hemoglobin level as a predictor of mortality after aortic valve replacement. J Cardiothorac Vasc Anesth. 2013;27(4):716-722.
Kiani S, Stebbins A, Thourani VH, et al. The effect and relationship of frailty indices on survival after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2020;13(2):219-231.
Hyde EC. Gastrointestinal bleeding in aortic stenosis. N Engl J Med. 1958;259(4):196-196.
Godino C, Lauretta L, Pavon AG, et al. Heyde's syndrome incidence and outcome in patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;61(6):687-689.
Eleid MF, Cabalka AK, Malouf JF, Sanon S, Hagler DJ, Techniques RCS. Outcomes for the treatment of paravalvular leak. Circ Cardiovasc Interv. 2015;8(8):e001945.
Eidet J, Dahle G, Bugge JF, et al. Transcatheter aortic valve implantation and intraoperative left ventricular function: a myocardial tissue Doppler imaging study. J Cardiothorac Vasc Anesth. 2015;29(1):115-120.
Gotzmann M, Lindstaedt M, Bojara W, Mügge A, Germing A. Hemodynamic results and changes in myocardial function after transcatheter aortic valve implantation. Am Heart J. 2010;159(5):926-932.
Muratori M, Fusini L, Tamborini G, et al. Sustained favourable haemodynamics 1 year after TAVI: improvement in NYHA functional class related to improvement of left ventricular diastolic function. Eur Heart J Cardiovasc Imaging. 2016;17(11):1269-1278.
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 38(36):2739-2791.
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 63(22):2438-2488.